Visiongain’s latest report, Pharmaceutical Contract Manufacturing Market Report 2026-2036, provides detailed forecasts and strategic analysis across drug type, services, scale of operation, and end-user segments, including technology trends, trade and supply chain dynamics, and competitive positioning.
The global pharmaceutical contract manufacturing market is projected to grow from US$171.00 billion in 2026 to US$367.06 billion by 2036, at a CAGR of 7.9% during the forecast period. The market is expected to add over US$196 billion in value, driven by increasing pharmaceutical R&D investment, expansion of outsourcing models, and rising demand for complex biologics and advanced therapies.
Key Market Insights
The global pharmaceutical contract manufacturing market will reach US$367.06 billion by 2036, growing at a CAGR of 7.9%
Growth is driven by increased outsourcing, biologics expansion, and R&D investment
Key regions: North America, Europe, Asia Pacific
Leading companies: Lonza, Thermo Fisher Scientific, Samsung Biologics, WuXi AppTec
Key trend: Shift towards advanced and biologics-focused manufacturing
Download Free Sample Report (incl. forecasts, market data, and methodology)
Market Drivers
Rising Outsourcing Across Pharmaceutical Value Chains
Pharmaceutical companies are increasingly outsourcing manufacturing to CDMOs to reduce capital expenditure, improve flexibility, and accelerate time-to-market. This trend is particularly strong among small and mid-sized biotech firms that lack internal manufacturing capabilities and rely on external partners across development and commercial stages.
Growth in Biologics and Advanced Therapies
The shift towards biologics, cell and gene therapies, and precision medicine is significantly increasing demand for specialised manufacturing capabilities. These therapies require complex production processes and high regulatory compliance, reinforcing reliance on experienced CDMOs with advanced infrastructure and technical expertise.
CDMOs are investing heavily in advanced manufacturing technologies, including continuous manufacturing, automated bioprocessing, and high-containment systems. These innovations are improving production efficiency, scalability, and quality control, enabling providers to meet growing demand for complex and high-potency products.
Trade & Supply Chain Dynamics
Global trade dynamics are increasingly shaping the pharmaceutical contract manufacturing market, with tariffs and geopolitical factors influencing supply chains and cost structures.
The market depends on globally distributed manufacturing networks, creating exposure to tariffs, regulatory changes, and policy shifts across major regions. At the same time, companies are prioritising supply chain resilience and regional diversification to reduce risk and maintain continuity.
Commercial Impact
Cost pressure: Rising input, compliance, and logistics costs are increasing manufacturing expenses
Supply chain shifts: Companies are diversifying sourcing and expanding regional production
Margin implications: CDMOs face pressure on export-oriented operations
Competitive positioning: Providers with multi-regional capacity gain advantage
Market Opportunities
Expansion in Emerging Manufacturing Hubs
Emerging markets such as India, China, Brazil, and Mexico are becoming key centres for contract manufacturing, supported by cost advantages, skilled labour, and improving regulatory frameworks. These regions are attracting increasing outsourcing demand from global pharmaceutical companies.
Growth in Cell and Gene Therapy Manufacturing
Cell and gene therapies represent a major growth opportunity, with increasing clinical activity and regulatory approvals driving demand for highly specialised manufacturing services. CDMOs with capabilities in vector production, cell processing, and GMP manufacturing are well positioned to capture this growth.
Competitive Landscape
The major players operating in the pharmaceutical contract manufacturing market include AbbVie Inc., Lonza, Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Recipharm, and Siegfried Holding AG.
These companies are focusing on capacity expansion, advanced technology investment, partnerships, and geographic expansion to strengthen their competitive positions.
Recent Developments
February 2026 – Aenova expanded semi-solid manufacturing and packaging capabilities in Germany
January 2026 – Siegfried acquired drug substance manufacturing assets from Noramco Group
January 2026 – Charles River Laboratories partnered with Gazi University on gene therapy CDMO collaboration
Frequently Asked Questions
What is driving growth in the pharmaceutical contract manufacturing market? Growth is driven by increasing outsourcing, expansion of biologics and advanced therapies, and sustained R&D investment.
How are trade and supply chain dynamics affecting the market? Tariffs and geopolitical factors are increasing costs and driving supply chain diversification.
Who are the leading companies in the market? Key players include Lonza, Thermo Fisher Scientific, Samsung Biologics, WuXi AppTec, and Catalent.
Download Free Sample Report (incl. forecasts, market data, and methodology)
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
